ClinicalTrials.gg
CompletedNCT03478319Updated Jul 18, 2019

A Study of ACE-2494 in Healthy Subjects

A Phase 1 interventional study of ACE-2494 or placebo in Healthy Volunteers, sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA. Completed at 1 site in Canada. Open to female participants aged 45 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-18.

Sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (part of Merck & Co., Inc) · Phase 1, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
Female
01

Study summary

The purpose of the study is to assess safety, tolerance, pharmacokinetic, and pharmacodynamics of single doses of ACE-2494 in healthy postmenopausal women.

Read the detailed description

Subjects will be evaluated for study inclusion/exclusion criteria during the screening period (within 4 weeks prior to Day -1) and eligible subjects who have signed the informed consent form (ICF) will be enrolled and treated with study drug (ACE-2494 or placebo) on Day 1. Subjects will be randomized (3:1, ACE-2494: placebo) to receive one dose of either ACE-2494 or placebo, respectively, on Day 1.

The primary objective of the study is to evaluate the safety and tolerability of single ascending doses of ACE-2494 in healthy postmenopausal women. The secondary objectives are to characterize the pharmacokinetic (PK) profile and pharmacodynamic (PD) effects, including serum biomarkers, fat, lean, and bone mass (DXA), muscle volume and intramuscular fat fraction (MRI).

02

Conditions studied

  • Healthy Volunteers

Keywords

  • ACE-2494
03

In context

Lead sponsor

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA is the lead sponsor of 26 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. women, with menopause defined by follicle stimulating hormone (FSH) level > 40 IU/L and either 12 months of spontaneous amenorrhea or at least 6 months post-surgical bilateral oophorectomy and/or hysterectomy
  2. Age 45-75 years
  3. (BMI) 18.5-32.0 kg/m2
  4. Clinical laboratory values that meet the following criteria prior to dosing on Day 1:

    1. (AST) and alanine aminotransferase (ALT) ≤ 2 x (ULN)
    2. Serum creatinine ≤ 1.5 x ULN
  5. Ability to adhere to the study visit schedule/procedures, and to understand and comply with protocol requirements
  6. Signed written

Exclusion criteria

Exclusion Criteria:

  1. Smokers (use of tobacco products within 3 months prior to screening)
  2. History of (HBsAg and HB core Ab), (HIV) antibody or active
  3. Positive drug or alcohol screen test at screening or on Day 1
  4. History of drug or alcohol abuse (as defined by the investigator) or required treatment for drug or alcohol use within 2 years of Day 1
  5. Donated or lost ≥ 500 mL of whole blood within 2 months prior to Day 1
  6. History of opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia) within 6 months prior to screening; serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., septicemia) within 3 months prior to screening
  7. History of severe allergic or anaphylactic reaction or to recombinant proteins or any other drugs
  8. Systemic therapy, statin medication, growth hormone, androgen, insulin, oral hormone replacement therapy or any other therapy (including ) with known or intended effects on muscle within 3 months prior to Day 1
  9. Anti , anti-coagulant, or any other therapy (including investigational) with known or intended effects on bleeding risk within 1 week prior to Day 1 (Daily low-dose aspirin is allowed)
  10. Treatment with another investigational drug, device, or approved therapy for investigational use within 30 days prior to Day 1; administration of a biological product in the context of a clinical research study within 90 days prior to Day 1
  11. Participation in another clinical trial involving intervention with or without an investigational drug or device at any time during the study period
  12. Unwilling or unable to maintain physical activity at baseline level for the duration of the study
  13. For Cohorts 4-6 only, any condition that would prevent MRI scanning or compromise the ability to obtain a clear and interpretable scan of the thigh (e.g., pacemaker, knee/hip replacement, metallic implant, extreme claustrophobia, etc.)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Cohort 1

    ACE-2494 or placebo 0.06 mg/kg SC Day 1

    Drug: ACE-2494 or placebo

  • Experimental
    Cohort 2

    ACE-2494 or placebo 0.2 mg/kg SC Day 1

    Drug: ACE-2494 or placebo

  • Experimental
    Cohort 3

    ACE-2494 or placebo 0.6 mg/kg SC Day 1

    Drug: ACE-2494 or placebo

  • Experimental
    Cohort 4

    ACE-2494 or placebo 1.0 mg/kg SC Day 1

    Drug: ACE-2494 or placebo

  • Experimental
    Cohort 5

    ACE-2494 or placebo 2.0 mg/kg SC Day 1

    Drug: ACE-2494 or placebo

  • Experimental
    Cohort 6

    ACE-2494 or placebo TBD (not to exceed 3.0 mg/kg SC) Day 1

    Drug: ACE-2494 or placebo

Interventions

  • DrugACE-2494 or placebo

    Recombination fusion protein

06

What researchers measure

Primary outcomes

  1. Number of participants with ACE-2494 treatment-related adverse events as assessed by CTCAE v5.0

    Adverse events (including both clinical observations and laboratory measurements), deemed related to ACE-2494 treat, will be recorded for each study subject

    Time frame: From initiation of treatment (Study Day 1) to end of follow-up period (Study Day 85)

Secondary outcomes

  1. Determination of ACE-2494 serum Cmax

    Determination of maximum serum concentration of ACE-2494 following subcutaneous administration

    Time frame: From initiation of treatment, Study Day (SD)1 to end of follow-up period (SD85)

  2. Determination of ACE-2494 serum Tmax

    Determination of time to maximum serum concentration of ACE-2494 following subcutaneous administration

    Time frame: From initiation of treatment, Study Day (SD)1 to end of follow-up period (SD85)

  3. Determination of ACE-2494 serum T1/2

    Determination of serum half-life of ACE-2494 following subcutaneous administration

    Time frame: From initiation of treatment, Study Day (SD)1 to end of follow-up period (SD85)

  4. Determination of ACE-2494 AUC

    Determination of the area under the serum concentration curve of ACE-2494 following subcutaneous administration

    Time frame: From initiation of treatment, Study Day (SD)1 to end of follow-up period (SD85)

  5. Quantitation of serum GDF8 following ACE-2494 treatment

    Quantitation of serum levels of growth differentiation factor (GDF)8 following treatment with ACE-2492

    Time frame: From initiation of treatment, Study Day (SD)1 to end of follow-up period (SD85)

  6. Quantitation of serum BSAP following ACE-2494 treatment

    Quantitation of serum levels of bone-specific alkaline phosphatase (BSAP) following treatment with ACE-2494

    Time frame: From initiation of treatment, Study Day (SD)1 to end of follow-up period (SD85)

  7. Quantitation of serum CTX following ACE-2494 treatment

    Quantitation of serum levels of carboxy-terminal collagen crosslinks (CTX) following treatment with ACE-2494

    Time frame: From initiation of treatment, Study Day (SD)1 to end of follow-up period (SD85)

  8. Quantitation of serum FSH following ACE-2494 treatment

    Quantitation of serum levels of follicle stimulating hormone (FSH) following treatment with ACE-2494

    Time frame: From initiation of treatment, Study Day (SD)1 to end of follow-up period (SD85)

  9. Determination of body composition following ACE-2494 treatment by DXA

    Regional and whole-body quantitation of fat mass by dual energy X-ray absorptiometry (DXA) following treatment with ACE-2494

    Time frame: From initiation of treatment, Study Day (SD)1 to end of follow-up period (SD85)

  10. Determination of body composition following ACE-2494 treatment by DXA

    Regional and whole-body quantitation of lean mass by dual energy X-ray absorptiometry (DXA) following treatment with ACE-2494

    Time frame: From initiation of treatment, Study Day (SD)1 to end of follow-up period (SD85)

  11. Determination of body composition following ACE-2494 treatment by DXA

    Regional and whole-body quantitation of bone mass by dual energy X-ray absorptiometry (DXA) following treatment with ACE-2494

    Time frame: From initiation of treatment, Study Day (SD)1 to end of follow-up period (SD85)

  12. Determination of thigh muscle volume and intramuscular fat following ACE-2494 treatment by MRI for patients in Cohorts 4-6 only

    Determination of total muscle volume in the thigh by magnetic resonance imaging (MRI)

    Time frame: From initiation of treatment, Study Day (SD)1 to end of follow-up period (SD85)

  13. Determination of thigh muscle volume and intramuscular fat following ACE-2494 treatment by MRI for patients in Cohorts 4-6 only

    Determination of intramuscular fat in the thigh by magnetic resonance imaging (MRI)

    Time frame: From initiation of treatment, Study Day (SD)1 to end of follow-up period (SD85)

07

Study locations

1 site
  • Syneos Health
    Québec, G1P0A2, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Jun 2019, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2018
First posted
Mar 27, 2018
StartActual
Feb 15, 2018
Primary completionActual
Jun 13, 2019
CompletionActual
Jun 17, 2019
Last update
Jul 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03478319
Responsible party
Sponsor
First posted
Mar 27, 2018
Start date
Feb 15, 2018
Primary completion
Jun 13, 2019
Completion
Jun 17, 2019
Last update
Jul 18, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion